PL406033A1 - Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers - Google Patents
Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markersInfo
- Publication number
- PL406033A1 PL406033A1 PL406033A PL40603313A PL406033A1 PL 406033 A1 PL406033 A1 PL 406033A1 PL 406033 A PL406033 A PL 406033A PL 40603313 A PL40603313 A PL 40603313A PL 406033 A1 PL406033 A1 PL 406033A1
- Authority
- PL
- Poland
- Prior art keywords
- diagnosing
- thyroid
- carcinoma
- mir
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Przedmiotem wynalazku jest sposób diagnozowania zmiany chorobowej, takiej jak nowotwór i/lub zmiana łagodna tarczycy u pacjenta, który to sposób obejmuje: - dostarczanie pochodzącej od pacjenta próbki biologicznej, - określanie ilości jednego lub więcej mikroRNA wybranego z grupy obejmującej miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p i miR-182-5p w próbce biologicznej, - porównywanie ekspresji mikroRNA z poziomem ekspresji mikroRNA w grupie kontrolnej, - diagnozowanie wystąpienia nowotworu /i/lub zmiany łagodnej u pacjenta, jeśli poziom ekspresji mikroRNA w próbce biologicznej jest zmieniony względem poziomu ekspresji obserwowanej w próbkach płynów biologicznych w grupie kontrolnej. Przedmiotem wynalazku jest także zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie tarczycy oraz zestaw do diagnozowania zmiany chorobowej.The subject of the invention is a method for diagnosing a lesion such as cancer and / or benign thyroid in a patient, which method comprises: - providing a patient-derived biological sample, - determining the amount of one or more microRNA selected from the group consisting of miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p and miR-182-5p in a biological sample, - comparison of microRNA expression with the level of microRNA expression in the control group, - diagnosing the occurrence of a tumor / and / or benign change in a patient if the level of microRNA expression in a biological sample is changed relative to the level of expression observed in biological fluid samples in the control group. The invention also relates to the use of a microRNA marker for diagnosing a thyroid lesion and a kit for diagnosing a lesion.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL406033A PL406033A1 (en) | 2013-11-14 | 2013-11-14 | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers |
PCT/IB2014/066057 WO2015071876A2 (en) | 2013-11-14 | 2014-11-14 | Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL406033A PL406033A1 (en) | 2013-11-14 | 2013-11-14 | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers |
Publications (1)
Publication Number | Publication Date |
---|---|
PL406033A1 true PL406033A1 (en) | 2015-05-25 |
Family
ID=53058217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL406033A PL406033A1 (en) | 2013-11-14 | 2013-11-14 | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers |
Country Status (2)
Country | Link |
---|---|
PL (1) | PL406033A1 (en) |
WO (1) | WO2015071876A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
DK3435084T3 (en) | 2012-08-16 | 2023-05-30 | Mayo Found Medical Education & Res | PROSTATE CANCER PROGNOSIS USING BIOMARKERS |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
WO2018039490A1 (en) | 2016-08-24 | 2018-03-01 | Genomedx Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
EP3571322B9 (en) | 2017-01-20 | 2023-10-04 | VERACYTE SD, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
CA3055925A1 (en) | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
CA3062716A1 (en) | 2017-05-12 | 2018-11-15 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
KR102649965B1 (en) * | 2019-01-11 | 2024-03-22 | 연세대학교 산학협력단 | Composition for Targeting Medullary Thyroid Cancer |
RU2705110C1 (en) * | 2019-04-10 | 2019-11-06 | Государственное бюджетное учреждение здравоохранения "Краевая клиническая больница N2" Министерства здравоохранения Краснодарского края | Method for differential diagnosis of thyroid neoplasms |
CN111286538B (en) * | 2020-02-13 | 2023-04-07 | 朱伟 | Circulating miRNA and carcinoembryonic miRNA markers related to pan-tumor auxiliary diagnosis and application thereof |
CN114196759B (en) * | 2021-12-31 | 2023-10-20 | 深圳市海普洛斯生物科技有限公司 | Pancreatic cancer biomarker of urine sample and application thereof |
CN116769922B (en) * | 2023-08-24 | 2023-11-24 | 四川大学华西医院 | Application of reagent for detecting circulating sEV RNA, kit and diagnostic system |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040214203A1 (en) | 2002-12-12 | 2004-10-28 | Oncotech, Inc. | Genes related to sensitivity and resistance to chemotherapeutic drug treatment |
US20060160114A1 (en) | 2004-12-02 | 2006-07-20 | Oncotech, Inc. | Reagents and methods for predicting drug resistance |
CN102943108B (en) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
US20080076674A1 (en) | 2006-07-06 | 2008-03-27 | Thomas Litman | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer |
EP2090665A2 (en) | 2006-10-20 | 2009-08-19 | Exiqon A/S | Novel human microRNAs associated with cancer |
WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
EP2806273B1 (en) | 2007-07-25 | 2017-09-06 | University of Louisville Research Foundation, Inc. | Exosome-associated microRNA as a diagnostic marker |
WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
WO2009143379A2 (en) | 2008-05-21 | 2009-11-26 | Fred Hutchinson Cancer Research Center | Use of extracellular rna to measure disease |
WO2010145035A1 (en) | 2009-06-19 | 2010-12-23 | Siu K W Michael | Renal cell carcinoma biomarkers |
EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
WO2012009499A2 (en) | 2010-07-15 | 2012-01-19 | Mayo Foundation For Medical Education And Research | Assessing thyroid neoplasms and treating cancer |
EP2640851A2 (en) * | 2010-11-17 | 2013-09-25 | Asuragen, Inc. | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
AU2012230835B2 (en) * | 2011-03-22 | 2016-05-05 | Cornell University | Distinguishing benign and malignant indeterminate thyroid lesions |
EP2505664B1 (en) * | 2011-03-30 | 2014-12-03 | Universität Leipzig | Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB) |
EP2771487A1 (en) * | 2011-10-27 | 2014-09-03 | Asuragen, INC. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
-
2013
- 2013-11-14 PL PL406033A patent/PL406033A1/en unknown
-
2014
- 2014-11-14 WO PCT/IB2014/066057 patent/WO2015071876A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2015071876A3 (en) | 2015-08-27 |
WO2015071876A2 (en) | 2015-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL406033A1 (en) | Method for diagnosing of thyroid papillous carcinoma, application of microRNA marker for diagnosing of the thyroid carcinoma, assessment of the disease progress and evaluation of patient and/or disease susceptibility to the proposed treatment and diagnostic set containing such markers | |
PL405648A1 (en) | Method for diagnosing primary hepatic carcinoma, application of microRNA marker for diagnosing the lesion within liver, assessment of the progression of disease and evaluation of patient's vulnerability and/or disease to the proposed treatment and diagnostic set containing such same markers | |
PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
CL2008001517A1 (en) | Device for determining the risk of melanoma progression comprising oligonucleotides of one or more melanoma prognostic markers (mpms) chosen from a selection group; procedure for determining the prognosis of melanoma in a patient; Procedure for determining the suitability of a melanoma patient for a drug trial. | |
PH12017501841A1 (en) | Method for discriminating symptom of hepatic disease | |
BR112016007864A2 (en) | Method for cancer prognosis and metastasis treatment | |
BR112014030750A2 (en) | METHOD FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER METASTASIS | |
MX2015011097A (en) | Inhibitors of histone demethylases. | |
MX2015001081A (en) | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk). | |
WO2013190075A3 (en) | Specific biomarkers for hepatocellular carcinoma (hcc) | |
BR112015011359A2 (en) | method to indicate presence or absence of aggressive prostate cancer | |
MX2023001945A (en) | Compositions and methods for screening solid tumors. | |
BR112015008255A2 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | |
MX2022012384A (en) | Compositions and methods for screening mutations in thyroid cancer. | |
WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
WO2013025952A3 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
BR112015009438A2 (en) | use of a ly75 binding antibody, method of detecting, diagnosing and / or evaluating or monitoring cancer progression and method for identifying an agent for the treatment or prophylaxis of a cancer | |
EA201490946A1 (en) | METHOD OF QUANTITATIVE EVALUATION OF CANCER TREATMENT | |
BR112016022407A2 (en) | compositions and methods related to prostate cancer diagnosis | |
EP3495502A3 (en) | Biomarkers for premature birth | |
BR112015029550A2 (en) | ANTI-VEGF ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, DIAGNOSIS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE CONTAINING THE SAME | |
MX359376B (en) | Method and kit for determination of free copper in serum. | |
WO2014181960A3 (en) | Fluorescent probe sensing tyrosine kinase and use thereof |